指南与共识乳腺癌

激素受体阳性、人表皮生长因子受体2阴性转移性乳腺癌的内分泌与靶向治疗——卡匹色替-氟维司群:ASCO快速推荐更新

Endocrine and Targeted Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer-Capivasertib-Fulvestrant: ASCO Rapid Recommendation Update.
指南 / 共识 · J Clin Oncol · 2024-03-13

ASCO快速推荐更新针对激素受体阳性、人表皮生长因子受体2阴性转移性乳腺癌,基于新出现且改变实践的数据,对卡匹色替联合氟维司群的推荐进行修订。更新遵循ASCO指南方法学手册,旨在及时传播更新推荐。

要点

  • ASCO快速推荐更新基于证据回顾修订卡匹色替-氟维司群推荐。
  • 更新遵循ASCO指南方法学手册的制定流程。
  • 指南不替代治疗医师的独立专业判断,不考虑患者个体差异。

核心结论

  • ASCO快速推荐更新针对激素受体阳性、人表皮生长因子受体2阴性转移性乳腺癌,基于新出现且改变实践的数据修订卡匹色替-氟维司群推荐。

研究设计与样本

  • ASCO快速推荐更新由证据回顾支持,并遵循ASCO指南方法学手册中概述的指南制定流程。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

ASCO Rapid Recommendation Updates highlight revisions to select ASCO guideline recommendations as a response to the emergence of new and practice-changing data. The rapid updates are supported by an evidence review and follow the guideline development processes outlined in the ASCO Guideline Methodology Manual. The goal of these articles is to disseminate updated recommendations, in a timely manner, to better inform health practitioners and the public on the best available cancer care options. Guidelines and updates are not intended to substitute for independent professional judgment of the treating provider and do not account for individual variation among patients. See appendix for disclaimers and other important information (Appendix 1 and Appendix 2, online only).

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Burstein HJ, DeMichele A, Fallowfield L, et al. Endocrine and Targeted Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer-Capivasertib-Fulvestrant: ASCO Rapid Recommendation Update. J Clin Oncol. 2024. PMID: 38478799. doi:10.1200/JCO.24.00248

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。